Linking process indicators and clinical/safety outcomes to assess the effectiveness of abatacept (ORENCIA) patient alert cards in patients with rheumatoid arthritis.
Abatacept
/ adverse effects
Adolescent
Adult
Antirheumatic Agents
/ adverse effects
Arthritis, Rheumatoid
/ diagnosis
Attitude of Health Personnel
Cross-Sectional Studies
Drug Hypersensitivity
/ etiology
Europe
Female
Health Knowledge, Attitudes, Practice
Humans
Immunocompromised Host
Male
Middle Aged
Opportunistic Infections
/ chemically induced
Patient Education as Topic
Reminder Systems
Retrospective Studies
Risk Assessment
Risk Factors
Surveys and Questionnaires
Treatment Outcome
Young Adult
PASS
educational material
effectiveness evaluation
patient alert card
pharmacoepidemiology
risk minimisation
survey
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
04
09
2019
revised:
01
02
2020
accepted:
01
04
2020
pubmed:
13
5
2020
medline:
22
4
2021
entrez:
13
5
2020
Statut:
ppublish
Résumé
Patient alert cards (PACs) for abatacept (ORENCIA) inform patients and healthcare professionals (HCPs) about the risk of infections and allergic reactions. The study evaluates the effectiveness of the PACs in rheumatoid arthritis patients and HCPs, using process indicators (awareness, receipt, utility, knowledge, behaviour) and outcomes. Surveys of patients and HCPs in five European countries. A retrospective chart review permitted linking clinical and safety outcomes with survey responses. Data on 190 patients and 79 HCPs (50 physicians and 29 nurses) were analysed. Sixty percent of patients were aware of the PAC, of whom 95% had received it. Knowledge of risk of infection was higher among patients who had received the PAC vs those who had not (64% vs 46%; P = .013). Infections leading to hospitalisation increased with decreasing patient survey global scores: scores of ≥67%, 34%-67% and ≤ 33% were associated with hospitalisation rates of 2.5%, 5.2% and 8.4%, respectively (P = .4). Among HCPs 90% were aware and 68% had accessed the PAC. More nurses than physicians were aware (93% vs 88%), had accessed (78% vs 74%), read (90% vs 59%), distributed (81% vs 66%) and explained the content (94% vs 43%) of the PAC. Knowledge of risk of infection was higher among HCPs who had (91%) vs those who had not (73%) accessed the PAC (P = .053). PACs were effective in improving knowledge of key safety messages in patients and HCPs. This novel study design bridges the gap of linking process indicators with outcomes in the same patients, thereby strengthening the clinical relevance of patient surveys.
Substances chimiques
Antirheumatic Agents
0
Abatacept
7D0YB67S97
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
664-674Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP)-Module XVI-Risk minimisation measures: selection of tools and effectiveness indicators (Rev 2); 2017.
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VIII - Post-authorisation safety studies (Rev 2); 2016.
Draugalis JR, Coons SJ, Plaza CM. Best practices for survey research reports: a synopsis for authors and reviewers. Am J Pharm Educ. 2008;72:11. https://doi.org/10.5688/aj720111.
American Association for Public Opinion Research. Standard Definitions Final Dispositions of Case Codes and Outcome Rates for Surveys; 2016. doi:https://doi.org/10.1038/nsmb.2010.
European Medicines Agency and Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP) Module XVI- Risk minimisation measures: selection of tools and effectiveness indicators (Rev 1); 2014.
Gridchyna I, Cloutier A-M, Nkeng L, Craig C, Frise S, Moride Y. Methodological gaps in the assessment of risk minimization interventions: a systematic review. Pharmacoepidemiol Drug Saf. 2014;23:572-579. https://doi.org/10.1002/pds.3596.
Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer NA. Lessons learned on the design and the conduct of post-authorization safety studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol. 2017;83:884-893. https://doi.org/10.1111/bcp.13165.
Smith MY, Andrea Russell B, Priya Bahri B, et al. The RIMES statement: a checklist to assess the quality of studies evaluating risk minimization programs for medicinal products. Drug Saf. 2018;41:389-401. https://doi.org/10.1007/s40264-017-0619-x.
ISPE. Whitepaper-evaluating the effectiveness of additional risk minimisation measures via surveys in Europe: challenges and recommendations; 2016.
Banerjee AK, Zomerdijk IM, Wooder S, Ingate S, Mayall SJ. Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation. Drug Saf. 2014;37:33-42.
Agyemang E, Bailey L, Talbot J. Additional risk minimisation measures for medicinal products in the European Union: a review of the implementation and effectiveness of measures in the UK by one marketing authorisation holder. Pharmaceut Med. 2017;31:101-112. https://doi.org/10.1007/s40290-017-0184-8.
Zomerdijk IM, Trifirò G, Sayed-Tabatabaei FA, Sturkenboom MCJM, Straus SMJM. Additional risk minimisation measures in the EU - are they eligible for assessment? Pharmacoepidemiol Drug Saf. 2013;22:1046-1053.
Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions - systematic review and methodological considerations. Br J Clin Pharmacol. 2018;84:419-433. https://doi.org/10.1111/bcp.13469.
Prieto L, Spooner A, Hidalgo-Simon A, Rubino A, Kurz X, Arlett P. Evaluation of the effectiveness of risk minimization measures. Pharmacoepidemiol Drug Saf. 2012;21:896-899.
Vora P, Artime E, Soriano-Gabarró M, Qizilbash N, Singh V, Asiimwe A. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European union electronic register of post-authorization studies. Pharmacoepidemiol Drug Saf. 2018;27:695-706. https://doi.org/10.1002/pds.4434.
Mazzaglia G, Straus SMJ, Arlett P, et al. Study design and evaluation of risk minimization measures: a review of studies submitted to the European medicines agency for cardiovascular, endocrinology, and metabolic drugs. Drug Saf. 2018;41:191-202. https://doi.org/10.1007/s40264-017-0604-4.
Artime E, Shui I, Mendez I, et al. Pre/posteffectiveness evaluation of updated additional risk minimisation measures foran orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet. Pharmacoepidemiol Drug Saf. 2020;29:103-110.
Lem J, Younus M, Aram JA, et al. Evaluation of the effectiveness of additional risk minimization measures for voriconazole in the EU: findings and lessons learned from a healthcare professional survey. Pharmaceut Med. 2019;33:121-133. https://doi.org/10.1007/s40290-019-00273-4.
Artime E, Qizilbash N, Garrido-Estepa M, et al. Are risk minimization measures for approved drugs in Europe effective? a systematic review. Expert Opin Drug Saf. 2019;18:443-454. https://doi.org/10.1080/14740338.2019.1612875.